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Tumors of the foot and ankle are rare, and the particular clinicopathologic features, therapeutic approach, and
outcomes in this setting are not well established. From January 2000 to December 2010, 72 patients with
primary musculoskeletal tumors of the foot and ankle, both benign and malignant, were treated at a single
institution. Of the 72 patients, 56% were female. The median age was 52 years. Of the 72 tumors, 62 (86.11%)
were located in the foot and 10 were located in the ankle; 63 (87.5%) were soft tissue tumors and 9 (12.5%)
were bone tumors. Overall, 56 (78%) were benign tumors and 16 (22%) were malignant tumors. The most
frequent soft tissue and bone diagnosis was giant cell tumor. The median follow-up period was 49 months. The
vast majority of the tumors were located in the foot. Benign tumors were dominant, outnumbering malignant
tumors by more than 3 to 1. The diversity of the histologic benign types was evident, with giant cell tumor,
angiomyoma, and lipoma the most frequent. Regarding the malignant tumors, a clear male predominance was
present, the median age was 45 years, and the most frequent tumor was synoviosarcoma. The 9-year overall
and disease-free survival rate was 65% and 40%, respectively.
 2013 by the American College of Foot and Ankle Surgeons. All rights reserved.Tumors arising in the foot and ankle are relatively rare (1–8).
Fewer than 2% of all sarcomas and fewer than 10% of soft tissue
sarcomas arise in this location (9). Owing to the rarity of these tumors,
the particular clinicopathologic features, therapeutic approach, and
outcomes in this setting are not well established. Also, in many cases,
an inadequate or late diagnosis of lesions arising in the foot and ankle
has been correlated with greater rates of recurrence. Another
important aspect is that complete surgical resection of malignant
tumors of the foot and ankle is particularly difﬁcult, because of the
anatomic complexity of this functional unit.
The objective of the present study was to present the clinical
outcomes of a series of 72 cases of tumors located in the foot and
ankle, treated at a musculoskeletal oncology referral center, during an
approximate 10-year period.
Patients and Methods
A review was conducted using a collection of clinical records of all patients with
histologically conﬁrmed primary musculoskeletal tumors of the foot and ankle, benign
and malignant, treated from January 2000 to September 2010, at a musculoskeletalo, MD, Department of Medical
Avenida Bissaya Barreto No. 98,
edo).
an College of Foot and Ankle Surgeontumor referral center. The patients were identiﬁed by searching through the informatic
database of the pathology department. The present study did not include patients with
pseudotumoral lesions, tumors treated with thermal ablation, or patients with meta-
static lesions located in the foot and ankle. Patients were excluded if their clinical
records were incomplete. The study was performed with the approval of the institu-
tional review board of our institution.
A total of 72 cases were identiﬁed, and data were obtained on age, gender,
anatomic location, histologic diagnosis, stage, treatment modality, surgery type,
surgical margins, chemotherapy regimen, radiation dose, recurrence site, therapy
for recurrence, treatment complications, treatment response, and interval to death
or last follow-up visit. The bone tumors were staged according to the Enneking/
Musculoskeletal Tumor Society staging system, and the soft tissue bone tumors
were staged using the American Joint Committee on Cancer staging system (10,11).
The functional outcome was not evaluated in the present study. Overall survival
was deﬁned as the interval in months from the diagnosis to the date of the last
follow-up visit or death. Disease-free survival was deﬁned as the interval in months
with no evidence of disease, after curative treatment of the initial neoplastic
disease.
Statistical Analysis
Overall survival and disease-free survival curves were constructed according to the
Kaplan-Meier method and compared using the log-rank test. The differences were
considered signiﬁcant if p < .05. The software used for the statistical analysis was SPSS,
version 19.0 (SPSS, Chicago, IL).
Results
A total of 72 patients with benign and malignant musculoskeletal
tumors of the foot and ankle were diagnosed and treated, during thes. All rights reserved.
Table 1
Characteristics, treatment, and outcomes of benign tumors of foot and ankle (n ¼ 56
patients)
Parameter Value
Age (y)
Median 54
Range 17–76
Gender
Male 22 (39%)
Female 34 (61%)
Location
Foot 48 (86%)
Forefoot 23
Midfoot 25
Hindfoot 0
Ankle 8 (14%)
Histologic type
Soft tissue 49 (88%)
Bone tumors 7 (12%)
Giant cell tumor 11 (19.8%)
Angiomyoma 7 (12.5%)
Lipoma 7 (12.5%)
Schwannoma 5 (8.9%)
Dermatoﬁbroma 4 (7.1%)
Angioleiomyoma 4 (7.1%)
Osteocondroma 3 (5.3%)
Fibroma 3 (5.3%)
Fibrocondroma 2 (3.6%)
Desmoid tumor 2 (3.6%)
Leiomyoma 2 (3.6%)
Hemangioma 2 (3.6%)
Other 4 (7.1%)
Treatment
Surgery 56 (100%)
Resection 53 (95%)
Amputation 3 (5%)
Outcome
Continuously disease free 54 (96%)
Local recurrence 2 (4%)
Average disease-free interval (mo) 52
Data presented as n (%), unless otherwise noted.
Table 2
Characteristics of malignant tumors of the foot and ankle (n¼ 16 tumors in 16 patients)
Parameter Value
Age (y)
Median 45
Range 15–75
Gender
Male 10 (62%)
Female 6 (38%)
Location
Foot 14 (88%)
Forefoot 5
Midfoot 8
Hindfoot 1
Ankle 2 (12%)
Histologic type
Soft tissue tumors 14 (88%)
Synoviosarcoma 5
Malignant ﬁbrous histiocytoma 2
Liposarcoma 2
Fibrosarcoma 2
Clear cell sarcoma 1
Leiomyosarcoma 1
Chondrosarcoma 1
Bone tumors 2 (12%)
Osteosarcoma 1
Fusocellular sarcoma 1
Stage
Soft tissue tumors
IA 2
IB 3
IIA 3
IIB 1
III 4
IV 1
Bone tumors
IIA 1
III 1
Data presented as n (%), unless otherwise noted.
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University Hospital (Coimbra, Portugal). Of the 72 patients, 40 (56%)
were female and 32 (44%) were male. The median patient age was
52 (range 15 to 76) years. Our sample included 56 benign tumors
(78%) and 16malignant tumors (22%). Of the 72 tumors, 63 (88%) were
soft tissue tumors and 9 (12%) were bone tumors; 62 (86%) were
located in the foot and 10 (14%) in the ankle. The follow-up period
ranged from 4 to 119 (median 49) months.
Benign Tumors
Of the 56 patients with benign tumors, 34 (61%) were female and
22 (39%) weremale. Themedian age of the patients was 54 years, with
a minimum age of 17 and a maximum age of 76. The follow-up period
ranged from 9 to 119 (median 56) months. Of the 56 benign tumors,
48 (86%) were located in the foot and 8 (14%) in the ankle. According
to the regions of the foot, 23 tumors were located in the forefoot and
25 in the midfoot. No benign tumors were located in the hindfoot.
There were 49 (88%) soft tissue tumors and 7 (12%) bone tumors. The
most frequent histologic diagnoses were giant cell tumor (GCT) in 11
(19.8%), angiomyoma in 7 (12.5%), lipoma in 7 (12.5%), and schwan-
noma in 5 (8.9%). All patients underwent surgery. The surgery type
was resection in 53 cases (95%) and amputation in 3 (5%). Two cases of
soft tissue tumors of the foot had initially been treated with resection
at another institution had local recurrence. One was a desmoid tumor
and onewas an angiolipoma. The average disease-free interval was 52
months. Both patients with local recurrence underwent resection;
however, the patient with the desmoid tumor also underwentcomplementary radiotherapy after surgery. Four months after treat-
ment of the recurrence, the desmoid tumor recurred again, and the
patient underwent amputation. None of the patients had evidence of
disease at the last follow-up. The characteristics, treatment, and
outcomes of the patients with benign tumors are summarized in
Table 1.
Malignant Tumors
Of the 16 patients with malignant tumors, 10 (62%) were male and
6 (38%) were female. The median patient age was 45 (range 15 to 75)
years. The follow-up period ranged from 3 to 110 (median 27)months.
Fourteen tumors (88%) were located in the foot and 2 (12%) in the
ankle. According to the regions of the foot, 5 tumors were located in
the forefoot, 8 in the midfoot, and 1 in the hindfoot. Of the 16
malignant tumors, 14 (88%) were soft tissue tumors and 2 (12%) were
bone tumors. The most frequent histologic diagnosis was synovio-
sarcoma in 5 cases (31%). Two patients had metastases at diagnosis.
The characteristics of the patients with malignant tumors are
summarized in Table 2.
Treatment
All patients underwent surgery. A signiﬁcant number of
patients underwent amputation (44%). The surgical margins were
wide or radical in 56% of the cases; 62% of the patients received
chemotherapy. Chemotherapy, used in the neoadjuvant, adjuvant,
or palliative setting, consisted of multiagent regimens containing,
in most cases, cysplatin, doxorubicin, methotrexate, etoposide,
Table 3
Treatment of malignant tumors of foot and ankle (n = 16 tumors in 16 patients)
Parameter n (%)
Treatment
Surgery 16 (100%)
Chemotherapy 10 (62%)
Radiotherapy 4 (26%)
Surgery (primary tumor)
Resection 9 (56%)
Amputation 7 (44%)
Surgical margins
Marginal 7 (44%)
Wide/radical 9 (56%)
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radiotherapy for locoregional disease control. No operative
mortality or major morbidity related to treatment occurred. All the
adverse effects of chemotherapy and radiotherapy were
manageable.
The treatment of patients with malignant tumors of the foot and
ankle is summarized in Table 3.Fig. 1. Overall survival of patients with malignant tumors of the foot and ankle (n = 16
tumors in 16 patients).Outcome
The median follow-up period for the patients with malignant
tumors of the foot and ankle was 27 (range 3 to 110) months. The
median disease-free interval was 8 (range 0 to 107) months. Most
patients had no clinical or radiologic evidence of disease recurrence at
the moment. Four patients developed metastases after initial treat-
ment and died of disease.
The 9-year overall and disease-free survival rate was 65% and 40%,
respectively. The outcome of the patients with malignant tumors of
the foot and ankle is summarized in Table 4 and Figs. 1 and 2.Soft Tissue Tumors
Of the 63 patients with soft tissue tumors, 37 (57%) were female and
27(43%)weremale.Theiragerangedfrom16to76(median53)years. The
median follow-up was 53 (range 6 to 119) months. Of the 63 soft tissue
tumors, 48 (76%) were benign and 15 (24%) were malignant; 57 (90%)
were located in the foot and6 (10%) in the ankle. According to the regions
of the foot, 24 tumorswere located in the forefoot, 32 in themidfoot, and
1 in the hindfoot. The most frequent histologic diagnoses were GCT in 8
(13%), angiomyoma in 7 (11%), lipoma in 7 (11%), schwannoma in 5 (8%),
andsynoviosarcoma in5 (8%). The characteristicsof thepatientswithsoft
tissue tumors are summarized in Table 5 and Fig. 3.Table 4
Outcome of patients with malignant tumors of the foot and ankle (n = 16 tumors in 16
patients)
Variable Value
Follow-up (mo)
Median 27
Range 3–110
Disease-free interval (mo)
Median 8
Range 0–107
Patient status
CDF 8 (50%)
NED 3 (19%)
AWD 1 (6%)
DOD 4 (25%)
Abbreviations: AWD, alive with disease; CDF, continuously disease free; DOD, dead of
disease; NED, no evidence of disease.Bone Tumors
Of the 9 patients with bone tumors, 3 were female and 6 were
male. Their age ranged from 15 to 75 (median 42) years. The median
follow-up was 29 (range 3 to 109) months. Of the 9 bone tumors, 7
were benign and 2 were malignant. The most frequent histologic
diagnosis was osteocondroma (3 cases). The characteristics of theFig. 2. Disease-free survival of patients with malignant tumors of the foot and ankle (n =
16 tumors in 16 patients).
Table 5
Characteristics of patients with soft tissue tumors of foot and ankle (n ¼ 63 patients)
Parameter Value
Age (y)
Median 53
Range 16–76
Gender
Male 27 (43%)
Female 37 (57%)
Location
Foot 57 (90%)
Forefoot 24
Midfoot 32
Hindfoot 1
Ankle 6 (10%)
Data presented as n (%), unless otherwise noted.
Table 6
Characteristics of patientswithbone tumors of foot and ankle (n = 9 tumors in 9patients)
Parameter Value
Age (y)
Median 42
Range 15–75
Gender (n)
Male 6
Female 3
Histologic diagnosis (n)
Benign
Giant cell tumor 3
Osteocondroma 3
Enchondroma 1
Malignant
Osteosarcoma 1
Fusocellular sarcoma 1
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location of the tumors is shown in Fig. 4.
Discussion
Given that tumors of the foot and ankle are rare, the particular
clinicopathologic features, therapeutic approach, and outcomes in this
setting have not been extensively studied. The objective of the present
study was to present the clinical outcomes of a series of 72 cases of
tumors located in the foot and ankle, treated at a musculoskeletal
oncology referral center, for a period of approximately 10 years.
Chou et al (12), in a 20-year retrospective review of 153 tumors of
the foot and ankle, found that benign lesions and soft tissue tumors
were dominant, just as was observed in our series. Moreover, both
studies revealed a slight female predominance. However, the median
agewas 30 years in the series by Chou et al (12), but in our reviewwas
signiﬁcantly older (52 years). However, that might be because our
center does not admit pediatric patients. In relationship to the
anatomic location, the foot tumors represented 86% of our sample,
a signiﬁcantlygreater percentage than that (66%) observed in the studyFig. 3. Histologic diagnoses of soft tissue tumors of thbyChouet al (12). In both studies,GCTwas themost frequent histologic
type in the benign, soft tissue, and bone subgroups, and synovio-
sarcoma was the most frequent malignant tumor. The median follow-
up period was longer in our study, which could be explained by the
greater percentage of benign tumors.Murari et al (6) published a series
of 255 patients with foot tumors, in which 84% of the cases were
benign. The most frequent benign tumor was also GCT and chon-
drosarcomawas themost frequent histologic type ofmalignant tumor.
Ozger et al (13) reported 16 cases of malignant tumors of the foot
and ankle from 1989 to 1998. They found male predominance,
a median age of 33 years, a more frequent tumor location in the foot
(75%), and a soft tissue tumor rate of 81%. These results were quite
similar to ours, except for the older median age in our study. In both
studies, the most frequent histologic type was synoviosarcoma. In
relation to multimodality treatment, the review by Ozger et al (13)
showed that 88% underwent limb salvage surgery, in most patients,
themarginswerewide, 81% received chemotherapy, and 69% received
radiotherapy. In our study, more patients underwent amputation
(44%), inmost cases, wide or radicalmarginswere obtained, and fewer
patients received chemotherapy (62%) and radiotherapy (26%). Ine foot and ankle (N = 63 tumors in 63 patients).
Fig. 4. Anatomic location of bone tumors of the foot and ankle.
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survival rates, despite a signiﬁcantly lower disease-free interval. This
was because our institution is a referral center receiving, from other
hospitals, some patients who have already undergone surgical resec-
tion with marginal margins, which results in the likelihood of local
recurrence within a short period. However, our aggressive multi-
modality therapeutic approach, once disease recurrence has devel-
oped, is justiﬁed by the better survival rates of our patients.
The most frequent histologic type in the benign, soft tissue, and
bone subgroups of our series was GCT. Soft tissue GCT, ﬁrst described
by Salm and Sissons (14) in 1972, is a rare neoplasm located in both
superﬁcial and deep soft tissue. It commonly involves the upper and
lower extremities. The differential diagnosis should include derma-
toﬁbroma, atypical ﬁbroxanthomas, plexiform ﬁbrohistiocytic tumor,
giant cellmalignantﬁbrous histocytoma, osteoclast-like giant cell-rich
leiomyosarcoma, extraskeletal osteosarcoma (15), nodular fasciitis
with giant cells, and epithelioid sarcoma. Most cases of GCT of the soft
tissue follow a benign clinical course but can be locally aggressive and
recur locally. Although metastases are infrequent, cases have been
reported ofmetastases to the lungs (16,17) and parotid glands (18). Our
series included 8 cases of soft tissue GCT, all located in the foot. The
surgery type for most of these patients was resection of the lesion. No
local recurrence or metastases developed. GCT of the bone was ﬁrst
recognized in 1818 (19), but it was not until 1940 that it was formally
distinguished fromother tumors of the bone, such as aneurysmal bone
cyst, chondroblastoma, andnonossifyingﬁbroma (20). GCTof the bone
is a relatively rare, benign, but locally aggressive, osteolytic skeletal
neoplasm of young adults. It accounts for approximately 3% to 5% of all
primary bone tumors and 15% to 20% of all benign bone tumors (21,22).
Most cases are solitary lesions; multicentric GCT of the bone accounts
for less than 1% of the total reported cases (23). The most commonly
affected sites are the epiphyses of the long bones. In about 2% to 3% of
cases, distant metastases occur, most often to the lungs, but the
outcome of these “benign implants” is favorable. Rarely, GCT of the
bone undergoes true malignant transformation (24). In our study, as
described inmost reported cases, the 3 cases of boneGCTwere solitary
lesions located in the distal tibia and ﬁbulawith no local recurrence or
metastatic disease.
The most common primary soft tissue malignant tumor in the foot
and ankle is synoviosarcoma (25). Synovial sarcoma can be histo-
pathologically divided into biphasic, monophasic ﬁbrous, monophasic
epithelial, and poorly differentiated types. In cases of the biphasic type,
both epithelial and spindle cells are present; therefore, the diagnosis is
relatively easy. However, in cases of the monophasic type, which has
homogeneouspatternsof spindle cells, immunohistochemical stainingis needed todistinguish this tumor fromother spindle cell-type tumors
such as ﬁbrosarcoma, hemangiopericytoma, leiomyosarcoma, and
spindle cell carcinoma (26). Synoviosarcoma often arises deep in the
soft tissue near a joint in the extremity, and the peak incidence is in the
second to ﬁfth decades (25). Our results were similar to those previ-
ously reported, showing that synoviosarcoma was also the most
frequent histologic type of malignant tumors. All 5 cases observed
were located in the foot. The mean patient age was 37 years. Only 1
patient who died of disease. The other patients have been either
continuouslydisease freeaftera complete response to initial treatment
or without evidence of disease, despite local recurrence and metas-
tases in the past.
In relation to the limitations of the present study, the retrospective
nature of the study is an important limitation because of the vari-
ability of some data registered in the clinical records. Also, patients
with incomplete records had to be excluded. Because the selection of
the cases was based on the informatic database of pathology
department, tumors usually treated by destruction of the lesion with
thermal ablation, such as osteoid osteoma, were not included in the
present study.
In conclusion, tumors of the foot and ankle are rare and are
associated with a peculiar clinical presentation, histologic diagnoses,
surgical and medical approach, and patient outcome. The adequate
diagnosis and treatment of foot and ankle tumors has a signiﬁcant
effect on the patient’s functional outcome. In our series of 72
patients, the vast majority of the tumors were located in the foot.
Benign tumors were dominant, outnumbering malignant tumors by
more than 3 to 1. The diversity of histologic benign types was
evident, with GCT, angiomyoma, and lipoma the most frequent. Two
cases were recurrent benign tumor: angiolipoma and desmoid
tumor. In the malignant tumors, there was a clear male predomi-
nance, the median age was 45 years, and the most frequent tumor
was synoviosarcoma. The peculiar anatomic compartments of the
foot and ankle are favorable to rapid spread of malignancies arising
in this location; therefore, aggressive surgical intervention is
frequently required. Multimodal treatment is often necessary in
these cases. The 9-year overall and disease-free survival rate was 65%
and 40%, respectively. Larger scale studies of patients with tumors of
the foot and ankle are needed to understand this rare subgroup of
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